Intraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer: a single-institution retrospective analysis

Springer Science and Business Media LLC - Tập 197 - Trang 812-819 - 2021
Raluca Stoian1,2, Thalia Erbes3,4, Constantinos Zamboglou1,2, Jutta Scholber1,2, Mark Gainey1,2, Ilias Sachpazidis1,2, Erik Haehl1,2, Simon K. B. Spohn1,2, Vivek Verma5, David Krug6, Alexander Rühle1,2,7, Ingolf Juhasz-Böss3, Anca-Ligia Grosu1,2, Nils H. Nicolay1,2,7, Tanja Sprave1,2
1Department of Radiation Oncology, University Hospital of Freiburg, Freiburg, Germany
2German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany
3Department of Obstetrics and Gynecology, Medical Center – University of Freiburg, Freiburg, Germany
4Faculty of Medicine, University of Freiburg, Freiburg, Germany
5Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, USA
6Department of Radiation Oncology, University Hospital Schleswig-Holstein, Kiel, Germany
7Department of Molecular and Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany

Tóm tắt

There are currently no data from randomized controlled trials on the use of intraoperative radiotherapy (IORT) as a tumor bed boost as part of a breast-conservation approach for breast cancer. This study retrospectively reviewed the safety and efficacy of IORT as a boost treatment at a tertiary cancer center. From 2015 to 2019, patients underwent breast-conserving surgery with axillary lymph node staging and a single dose of 20 Gy IORT with 50-kV photons, followed by whole-breast irradiation (WBI) and adjuvant systemic therapy (if applicable). Patients were followed for assessment of acute and late toxicities (using the Common Terminology Criteria for Adverse Events version 5.0) at 3–6-month intervals. Outcomes included ipsilateral (IBTR) and contralateral breast progression-free survival (CBE), distant metastasis-free survival (DMFS), and overall survival (OS). Median follow-up for the 214 patients was 28 (range 2–59) months. Most patients had T1 disease (n = 124) and were clinically node negative. Only few patients had high-grade and/or triple-negative disease. The vast majority of patients underwent sentinel node biopsy, and 32 (15%) required re-resection for initially positive margins. Finally, all tumor bed margins were clear. Nine (4.2%) and 48 (22.4%) patients underwent neoadjuvant and adjuvant chemotherapy, respectively. WBI was predominantly performed as conventionally fractionated WBI (n = 187, 87.4%), and the median time from BCS to WBI was 54.5 days. IORT was delivered with a single dose of 20 Gy. The median WBI dose was 50 Gy (range 29.4–50.4 Gy). No patients experienced grade 4 events; acute grade 3 toxicities were limited to 17 (8%) cases of radiation dermatitis. Postoperative toxicities were mild. After WBI only one case of late grade ≥ 2 events was reported. There were two recurrences in the tumor bed and one contralateral breast event. This investigation provides additional preliminary data supporting the using of IORT in the boost setting and corroborates the existing literature. These encouraging results should be prospectively validated by the eventual publication of randomized studies such as TARGIT‑B.

Tài liệu tham khảo

Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716 Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J et al (2015) Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16(1):47–56 Harris EER, Small W Jr (2017) Intraoperative radiotherapy for breast cancer. Front Oncol 7:317 Pilar A, Gupta M, Ghosh Laskar S, Laskar S (2017) Intraoperative radiotherapy: review of techniques and results. ecancer 11:750 Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M et al (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5‑year results for local control and overall survival from the TARGIT‑A randomised trial. Lancet 383(9917):603–613 Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C et al (2013) Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 14(13):1269–1277 Fastner G, Reitsamer R, Urbanski B, Kopp P, Murawa D, Adamczyk B et al (2020) Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): First results of a prospective multicenter trial (NCT01343459). Radiother Oncol 146:136–142 Valente SA, Tendulkar RD, Cherian S, Shah C, Ross DL, Lottich SC, Laronga C, Broman KK, Donnelly ED, Bethke KP, Shaw C, Lockney NA, Pederson A, Rudolph R, Hasselle M, Kelemen P, Hermanto U, Ashikari A, Kang S, Hoefer RA, McCready D, Fyles A, Escallon J, Rohatgi N, Graves J, Graves G, Willey SC, Tousimis E, Riley L, Deb N, Tu C, Small W Jr, Grobmyer SR (2021) TARGIT‑R (retrospective): 5‑year follow-up evaluation of intraoperative radiation therapy (IORT) for breast cancer performed in North America. Ann Surg Oncol 28(5):2512–2521. https://doi.org/10.1245/s10434-020-09432-3. PMID: 33433786 Coombs NJ, Coombs JM, Vaidya UJ, Singer J, Bulsara M, Tobias JS et al (2016) Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT‑A trial centres and two UK NHS hospitals offering TARGIT IORT. BMJ Open 6(5):e10703 Strnad V, Hannoun-Levi JM, Guinot JL, Lossl K, Kauer-Dorner D, Resch A, Recommendations from GEC ESTRO Breast Cancer Working Group (I) (2015) Target definition and target delineation for accelerated or boost Partial Breast Irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery. Radiother Oncol 115(3):342–348 Wenz F, Welzel G, Blank E, Hermann B, Steil V, Sutterlin M et al (2010) Intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X‑rays: the first 5 years of experience with a novel approach. Int J Radiat Oncol Biol Phys 77(5):1309–1314 Pez M, Keller A, Welzel G, Abo-Madyan Y, Ehmann M, Tuschy B et al (2020) Long-term outcome after intraoperative radiotherapy as a boost in breast cancer. Strahlenther Onkol 196(4):349–355 Wenz F, Welzel G, Keller A, Blank E, Vorodi F, Herskind C et al (2008) Early initiation of external beam radiotherapy (EBRT) may increase the risk of long-term toxicity in patients undergoing intraoperative radiotherapy (IORT) as a boost for breast cancer. Breast 17(6):617–622 Kaiser J, Reitsamer R, Kopp P, Gaisberger C, Kopp M, Fischer T et al (2018) Intraoperative electron radiotherapy (IOERT) in the treatment of primary breast cancer. Breast Care 13(3):162–167 Fastner G, Hauser-Kronberger C, Moder A, Reitsamer R, Zehentmayr F, Kopp P et al (2016) Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery. Strahlenther Onkol 192(1):1–7 Fastner G, Reitsamer R, Ziegler I, Zehentmayr F, Fussl C, Kopp P et al (2015) IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer—results of a case series after 5‑year follow-up. Int J Cancer 136(5):1193–1201 Belletti B, Vaidya JS, D’Andrea S, Entschladen F, Roncadin M, Lovat F et al (2008) Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res 14(5):1325–1332 Fabris L, Berton S, Citron F, D’Andrea S, Segatto I, Nicoloso MS et al (2016) Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene 35(37):4914–4926 Clough KB, Kaufman GJ, Nos C, Buccimazza I, Sarfati IM (2010) Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. Ann Surg Oncol 17(5):1375–1391 Yang Z, Chen J, Hu W, Pan Z, Cai G, Yu X et al (2010) Planning the breast boost: how accurately do surgical clips represent the CT seroma? Radiother Oncol 97(3):530–534 Goldberg H, Prosnitz RG, Olson JA, Marks LB (2005) Definition of postlumpectomy tumor bed for radiotherapy boost field planning: CT versus surgical clips. Int J Radiat Oncol Biol Phys 63(1):209–213 Steel GG, Deacon JM, Duchesne GM, Horwich A, Kelland LR, Peacock JH (1987) The dose-rate effect in human tumour cells. Radiother Oncol 9(4):299–310 Whelan TJ, Kim DH, Sussman J (2008) Clinical experience using hypofractionated radiation schedules in breast cancer. Semin Radiat Oncol 18(4):257–264 Williams MV, Denekamp J, Fowler JF (1985) A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys 11(1):87–96 Group ST, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371(9618):1098–1107 Group ST, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9(4):331–341 Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086–1094 Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J et al (2006) Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 7(6):467–471 Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L et al (2002) Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 94(15):1143–1150 Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR et al (2010) Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5‑year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncol 11(3):231–240 Brunt AM, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A et al (2020) Ten-year results of FAST: a randomized controlled trial of 5‑fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol 38(28):3261–3272 Gupta A, Khan AJ, Yegya-Raman N, Sayan M, Ahlawat S, Ohri N et al (2019) 5‑year results of a prospective phase 2 trial evaluating 3‑week hypofractionated whole breast radiation therapy inclusive of a sequential boost. Int J Radiat Oncol Biol Phys 105(2):267–274 Choi KH, Ahn SJ, Jeong JU, Yu M, Kim JH, Jeong BK et al (2020) Postoperative radiotherapy with intensity-modulated radiation therapy versus 3‑dimensional conformal radiotherapy in early breast cancer: a randomized clinical trial of KROG 15-03. Radiother Oncol 154:179–186 Krug D, Koder C, Hafner MF, Arians N, Harrabi SB, Koerber SA et al (2020) Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. Radiat Oncol 15(1):235 Joseph K, Vos LJ, Gabos Z, Pervez N, Chafe S, Tankel K, Warkentin H, Ghosh S, Amanie J, Powell K, Polkosnik LA, Horsman S, MacKenzie M, Sabri S, Parliament MB, Mackey J, Abdulkarim B (2021) Skin toxicity in early breast cancer patients treated with field-in-field breast intensity-modulated radiotherapy versus helical inverse breast intensity-modulated radiotherapy: results of a phase III Randomised controlled trial. Clin Oncol (R Coll Radiol) 33(1):30–39. https://doi.org/10.1016/j.clon.2020.07.005. PMID: 32711920 Blank E, Kraus-Tiefenbacher U, Welzel G, Keller A, Bohrer M, Sutterlin M et al (2010) Single-center long-term follow-up after intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage x‑rays. Ann Surg Oncol 17(Suppl 3):352–358 Chang DW, te Marvelde L, Chua BH (2014) Prospective study of local control and late radiation toxicity after intraoperative radiation therapy boost for early breast cancer. Int J Radiat Oncol Biol Phys 88(1):73–79 Fastner G, Sedlmayer F, Merz F, Deutschmann H, Reitsamer R, Menzel C et al (2013) IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysis. Radiother Oncol 108(2):279–286 Ivaldi GB, Leonardi MC, Orecchia R, Zerini D, Morra A, Galimberti V et al (2008) Preliminary results of electron intraoperative therapy boost and hypofractionated external beam radiotherapy after breast-conserving surgery in premenopausal women. Int J Radiat Oncol Biol Phys 72(2):485–493 Lemanski C, Azria D, Thezenas S, Gutowski M, Saint-Aubert B, Rouanet P et al (2006) Intraoperative radiotherapy given as a boost for early breast cancer: long-term clinical and cosmetic results. Int J Radiat Oncol Biol Phys 64(5):1410–1415 Sedlmayer F, Reitsamer R, Fussl C, Ziegler I, Zehentmayr F, Deutschmann H et al (2014) Boost IORT in breast cancer: body of evidence. Int J Breast Cancer 2014:472516 Vaidya JS, Baum M, Tobias JS, Wenz F, Massarut S, Keshtgar M et al (2011) Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery. Int J Radiat Oncol Biol Phys 81(4):1091–1097 Wong WW, Pockaj BA, Vora SA, Halyard MY, Gray RJ, Schild SE (2014) Six-year outcome of a prospective study evaluating tumor bed boost with intra-operative electron irradiation followed by whole-breast irradiation for early-stage breast cancer. Breast J 20(2):125–130
Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 197

812-819

Thông tin tác giả